September 14, 2022
On September 8, Willkie client NextPharma, a portfolio company of CapVest Partners, announced it had reached an agreement to purchase a pharmaceutical manufacturing site in Asker, Norway, from Takeda, a global biopharmaceutical leader headquartered in Japan.
The transaction is subject to regulatory approvals and is expected to complete in March 2023, with the approximately 170 manufacturing employees transferring to NextPharma.
NextPharma is a leading European Contract Development and Manufacturing Organization (CDMO) offering specialized services in oral and topical (including sterile ophthalmic) finished dosage forms to a broad base of global pharmaceutical customers. With the intended acquisition, NextPharma plans to continue providing excellent levels of quality and service delivery to the site’s existing customers, in addition to developing and broadening its technology offering into chewable tablets.
Willkie previously advised NextPharma on its acquisition of the Ploermel and Edinburgh production sites of Lonza Group AG, a Swiss multinational chemicals and biotechnology company.
The Willkie deal team is led by London partner Andrew Gray and includes associates Meghal Mehta and Ben Pearlman.
